Disability and health‐related quality of life in Chinese patients with rheumatoid arthritis: A cross‐sectional study

Zhou, Yifeng; Wang, Xiuru; An, Yuan; Zhang, Xiaoying; Han, Shuling; Li, Xiaofeng; Wang, Lizhi; Wang, Caihong; Wang, Yongfu; Yang, Rong; Wang, Guochun; Lü, Xin; Zhu, Ping; Chen, Lina; Liu, Jinting; Jin, Hongtao; Lei, Yu; Sun, Lin; Wei, Ping; Wang, Jun-Xiang; Chen, Haiying; Shu, Rong; Zhang, Zhuoli; Li, Guangtao; Li, Zhenbin; Yang, Jing; Li, Junfang; Jia, Bin; Zhang, Fengxiao; Tao, Jie-Mei; Lin, Jianhao; Wei, Qiumei; Liu, Xiaomin; Ke, Dan; Hu, Shaoxian; Ye, Cong; Yang, Xia; Li, Hao; Huang, Cibo; Gao, Ming; Li, Xing-Fu; Song, Lijun; Wang, Yi; Wang, Xiaoyuan; Mu, Rong; Su, Yin; Li, Zhanguo

doi:10.1111/1756-185x.13345

Cited by 19 publications

(14 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 RA contributes to impaired physical function, severe disability, and poor quality of life. 2 The high cost of RA treatment also poses a huge economic burden. The average all-cause health care costs were reported to be $32,493 per year for RA patients receiving 1 synthetic disease-modifying antirheumatic drug in the United States.…”

mentioning

confidence: 99%

Pharmacokinetics and Bioequivalence of 2 Immediate‐Release Tofacitinib Tablet Formulations in Chinese Healthy Volunteers Under Fasting and Fed Conditions

Liu

Deng

et al. 2020

Clinical Pharm in Drug Dev

View full text Add to dashboard Cite

The purpose of this study was to evaluate the bioequivalence of a generic immediate-release tofacitinib tablet versus a brand-named immediate-release tofacitinib tablet under fasting and fed conditions, and the food effect on pharmacokinetic profiles of the both formulations. This randomized, open-label, 2-period, crossover, bioequivalence study included 52 healthy Chinese subjects (fasting cohort: n = 26; fed cohort: n = 26). The subjects were assigned to receive a single 5-mg dose of generic or brand-named tofacitinib. Blood samples were collected at predosing and up to 14 hours after dosing. Tofacitinib concentrations in plasma were analyzed by high-performance liquid chromatography-tandem mass spectrometry. Safety was monitored. There were no significant differences in maximum plasma concentration, area under the plasma concentration-time curve from time zero to time t (AUC 0-t ), AUC from time zero to infinity (AUC 0-∞ ) , and terminal elimination half-life between the test and reference formulations (all P > .05); high-fat food had no significant effect on AUC 0-t , AUC 0-∞, or terminal elimination half-life of immediate-release tofacitinib tablets (all P > .05). The 90% confidence intervals of the test/reference ratios of log-transformed maximum plasma concentration, AUC 0-t , and AUC 0-∞ were within the range of 80% to 125% under both fasting and fed conditions. No serious adverse events were reported. The 2 formulations of immediate-release tofacitinib tablets are bioequivalent and well tolerated under both fasting and fed conditions in healthy Chinese volunteers. Food had no clinically relevant effects on drug exposure of tofacitinib.

show abstract

mentioning

confidence: 99%

Pharmacokinetics and Bioequivalence of 2 Immediate‐Release Tofacitinib Tablet Formulations in Chinese Healthy Volunteers Under Fasting and Fed Conditions

Liu

Deng

et al. 2020

Clinical Pharm in Drug Dev

View full text Add to dashboard Cite

show abstract

“…RA is a common internal medical disease mainly affected by both environmental and genetic factors [51]. If not treated promptly, it may lead to joint deformity or even complete loss of joint function, thus affecting the daily activities and working abilities of patients, and have high disability and teratogenic rate [52]. WM treatment plays a role in relieving inflammation, reducing pain, and slowing joint damage; though the overall effects are positive, there are deficiencies, such as more adverse reactions and expensive costs, that ought to by no means be ignored.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Integrated Traditional Chinese Medicine and Western Medicine on the Treatment of Rheumatoid Arthritis: A Meta‐Analysis

Xing

et al. 2020

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. Integrated therapy of traditional Chinese medicine (TCM) and Western medicine (WM) has gradually been applied to the treatment of rheumatoid arthritis (RA). Recently published studies have provided a wealth of data and information about the effectiveness of combination treatments, but high-quality evidence-based meta-analysis on this issue is not available yet. This study was conducted to compare and evaluate the efficacy and safety of the integrated therapy for RA. Methods. PubMed, EMBASE, and the Cochrane Library were searched up to January 2020. Randomized controlled trials (RCTs) that compared the efficacy and safety of integrative TCM-WM with WM alone for RA were included. The outcome measures contained therapeutic effects (TEs), tender joint count (TJC), swollen joint count (SJC), duration of morning stiffness (DMS), grip strength (GS), disease activity score in 28 joints (DAS28), rheumatoid factor (RF), anti-cyclic peptide containing citrulline (anti-CCP), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and adverse events (AEs) to assess the efficacy and safety of different treatments. Results. A total of 20 RCTs with 2269 patients met the inclusion criteria. TCM used in these studies included Chinese herbal decoctions and tablets or capsules made from herbs and their extracts, while WM included disease-modifying antirheumatic drugs (DMARDs), nonsteroidal anti-inflammatory drugs (NSAIDs), and glucocorticoids (GC). Compared with patients receiving WM treatment alone, patients with integrative TCM-WM treatment showed better TEs (OR = 3.03, 95% CI [2.36, 3.88]). The integrative treatment group showed reductions in TJC (MD = −1.17, 95% CI [−2.12, −0.21]), SJC (MD = −0.87, 95% CI [−1.85, 0.10]), DMS (SMD = −0.69, 95% CI [−0.98, −0.41]), DAS28 (MD = −0.43, 95% CI [−0.57, −0.29]), RF (SMD = −0.59, 95% CI [−0.91, −0.27]), anti-CCP (SMD = −0.21, 95% CI [−0.36, −0.06]), ESR (MD = −8.36, 95% CI [−12.60, −4.12]), and CRP (MD = −6.73, 95% CI [−9.38, −4.08]), and increment in GS (SMD = 0.12, 95% CI [−0.63, 0.87]). AEs, especially gastrointestinal disorders, abnormal liver function, leukopenia, skin allergies and rashes, headaches and dizziness, and alopecia, significantly decreased (OR = 0.37, 95% CI [0.29, 0.47]) in the integrative treatment group. Conclusions. The findings of this meta-analysis indicate that integrative TCM-WM could obtain effective and safe results in the treatment of RA. Using TCM as an adjunctive therapy in RA has great prospects for further development.

show abstract

“…RA can occur at any age, and is most commonly seen in patients with 20-50 years old (26). RA is mostly a recurrent disease with high disability rate and poor prognosis (27). To date, anti-TNF therapy has been to carry out a further study.…”

Section: Discussionmentioning

confidence: 99%

Mining biomarkers for the occurrence, development and therapeutic response to infliximab of rheumatoid arthritis based on weighted gene co-expression network analysis

Wang

Zhang

Chen

et al. 2020

Preprint

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a chronic systemic autoimmune and recurrent disease characterized by joint lesion with high disability rate and poor prognosis. Although anti-TNF therapy (infliximab) has been validated to be effective in controlling the symptoms of RA, more than one-third of patients cannot benefit from anti-TNF therapy. Therefore, it is critical to explore novel biomarkers associated with the occurrence and development of the disease, and therapeutic response of infliximab treatment. In this study, we first analyzed differentially expressed genes (DEGs) between RA patients and healthy controls. Subsequently, WGCNA was used to analyze the co-expression module (tan module) associated with the therapeutic response of infliximab treatment in RA, which further found that the genes (a total of 102) in the module tan were also the DEGs between RA patients and healthy controls (confirming that the close correlation of these genes with the occurrence and development of RA). Subsequently, enrichment analysis revealed that these 102 genes were mainly related to the body’s inflammatory immune response and the functions of NOD-like receptor signaling pathway as well as miR-146a-5p. Moreover, protein-protein interaction (PPI) was constructed on the 102 genes, followed by mining the key genes in the network (a total of 14 genes) by topological analysis. Finally, we confirmed that 10 genes (OAS1, STAT1, IFIT3, IFIT2, IFI6, RSAD2, OASL, GBP2, IRF7 and IFIT1) were potential biomarkers for the occurrence and development, as well as the therapeutic response against infliximab treatment in RA by analyzing the differences in the expressions of these genes between RA and healthy control samples, as well as drug response and non-response samples. Therefore, this study can provide guidance on medication selection and prognostic prediction of RA patients for clinicians, which can also identify relevant genes to provide therapeutic targets for precise medicine.

show abstract

Disability and health‐related quality of life in Chinese patients with rheumatoid arthritis: A cross‐sectional study

Abstract: Aim:The objective of this study was to evaluate the impact of rheumatoid arthritis (RA) on physical function and health-related quality of life (HRQoL) in China.

Cited by 19 publications

References 24 publications

Pharmacokinetics and Bioequivalence of 2 Immediate‐Release Tofacitinib Tablet Formulations in Chinese Healthy Volunteers Under Fasting and Fed Conditions

Pharmacokinetics and Bioequivalence of 2 Immediate‐Release Tofacitinib Tablet Formulations in Chinese Healthy Volunteers Under Fasting and Fed Conditions

Efficacy and Safety of Integrated Traditional Chinese Medicine and Western Medicine on the Treatment of Rheumatoid Arthritis: A Meta‐Analysis

Mining biomarkers for the occurrence, development and therapeutic response to infliximab of rheumatoid arthritis based on weighted gene co-expression network analysis

Contact Info

Product

Resources

About